Search

Panel-based Genetic Diagnostic Testing for Inherited Eye Diseases is Highly Accurate and More Sensitive than Exome Sequencing Departmental investigators and colleagues in the HMS Ophthalmology Ocular Genomics Institute (OGI) recently reported the development and characterization of a comprehensive...

How biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease. Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined. Anti-VEGF treatments have...

Designed for practicing ophthalmologists, Eye Insights provides practical and relevant best practice information from Mass. Eye and Ear specialists in an easy-to-read format. Published twice a year, this clinical newsletter is mailed to 18,000 practicing ophthalmologists nationwide and features a...

While significant progress has been achieved in treating retinal diseases, researchers at Mass. Eye and Ear/Schepens Eye Research Institute remain deeply committed to improving current therapies, refining diagnostic tools, and developing new therapies that leverage advances in biotechnology and...

A Revolutionary Technology Dr. Claes H. Dohlman’s most notable achievement is the Boston Keratoprosthesis (KPro), a collar button design keratoprosthesis composed of a front plate with a stem, which houses the optical portion of the device, and a back plate with a slit. Available in Type I and Type...

Advances in postoperative care have greatly improved the clinical success of the Boston KPro. Common complications such as inflammation and infection are significantly lower with today’s prophylactic drug regimens. Innovative devices have also improved postoperative management of KPro. Soft contact...